Inverse relationship between fasting direct bilirubin and metabolic syndrome in Korean adults

Clinica Chimica Acta

Volumn 411, Issue 19-20, 2010, Pages 1496-1501

  Hwang, Hee Jin ^a   Kim, Sang Hwan ^a  

^a Kwandong University College of Medicine   (South Korea)

Author keywords

Bilirubin; Direct bilirubin; Indirect bilirubin; Metabolic syndrome

Indexed keywords

BILIRUBIN; BILIRUBIN GLUCURONIDE;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; ETHNIC GROUP; EXERCISE; FATTY LIVER; FEMALE; HUMAN; KOREAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATIENT SELECTION; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING;

EID: 77955057984     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.06.003     Document Type: Article

References (46)

1. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
2. Laaksonen D.E., Lakka H.M., Niskanen L.K., et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002, 156:1070-1077.
3. Hanson R.L., Imperatore G., Bennett P.H., et al. Components of the metabolic syndrome and incidence of type 2 diabetes. Diabetes 2002, 51:3120-3127.
4. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005, 112:2735-2752.
5. Mohamed-Ali V., Goodrick S., Rawesh A., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997, 82:4196-4200.
6. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity linked insulin resistance. Science 1993, 259:87-91.
7. Tracy R.P., Lemaitre R.N., Psaty B.M., et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project. Arterioscler Thromb Vasc Biol 1997, 17:1121-1127.
8. Koenig W., Sund M., Fröhlich M., et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99:237-242.
9. Rohde L.E., Hennekens C.H., Ridker P.M. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 1999, 84:1018-1022.
10. Jaundice Steven D.L. Sleisenger and Fordtran's gastrointestinal and liver disease 2006, 301-314. Saunders. 8th ed. Feldman (Ed.).
11. Baranano D.E., Rao M., Ferris C.D., et al. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A 2002, 99:16093-16098.
12. Bulmer A.C., Blanchfield J.T., Toth I., et al. Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis 2008, 199:390-396.
13. Schwertner H.A., Jackson W.G., Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994, 40:18-23.
14. Hopkins P.N., Wu L.L., Hunt S.C., et al. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1996, 16:250-255.
15. Erdogan D., Gullu H., Yildirim E., et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 2006, 184:431-437.
16. Perlstein T.S., Pande R.L., Beckman J.A., et al. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol 2008, 28:166-172.
17. Djousse L., Levy D., Cupples L.A., et al. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 2001, 87:1196-1200.
18. Temme E.H., Zhang J., Schouten E.G., Kesteloot H. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 2001, 12:887-894.
19. Troughton J.A., Woodside J.V., Young I.S., et al. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prev Rehabil 2007, 14:79-84.
20. Madhavan M., Wattingney W.A., Srinivasan S.R., et al. Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults. Atherosclerosis 1997, 131:107-113.
21. Torgerson J.S., Lindroos A.K., Sjostrom C.D., et al. Are elevated aminotransferases and decreased bilirubin additional characteristics of the metabolic syndrome?. Obes Res 1997, 5(2):105-114.
22. Lin L.Y., Kuo H.K., Hwang J.J., et al. Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 2009, 203:563-568.
23. Okada M., Matsui H., Ito Y., et al. Low density lipoprotein cholesterol can be chemically measured: a new superior method. J Lab Clin Med 1998, 132:195-201.
24. Tokuda K., Tanimoto K. New method of measuring serum bilirubin using vanadic acid. Jpn J Clin Chem 1993, 22:116-122.
25. Lee S.Y., Park H.S., Kim D.J., et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. Diab Res Clin Pract 2007, 75:72-80.
26. Troughton J.A., Woodside J.V., Young I.S., et al. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prev Rehabil 2007, 14:79-84.
27. Kronenberg F., Coon H., Gutin A., et al. A genome scan for loci influencing anti-atherogenic serum bilirubin levels. Eur J Hum Genet 2002, 10:539-546.
28. Endler G., Hamwi A., Sunder-Plassmann R., et al. Is low serum bilirubin an independent risk factor for coronary artery disease in men but not in women?. Clin Chem 2003, 49:1201-1204.
29. Stocker R., Yamamoto Y., McDonagh A.F., et al. Bilirubin is an antioxidant of possible physiological importance. Science 1987, 235:1043-1046.
30. Nakagami T., Toyomura K., Kinoshita T., et al. A beneficial role of bile pigments as an endogenous tissue protector: anticomplement effects of biliverdin and conjugated bilirubin. Biochim Biophys Acta 1993, 1158:189-193.
31. Wolkoff A.W. The hyperbilirubinemias: Harrison's principles of internal medicine 2005, 1817-1821. McGraw-Hill, New York, NY. 16th ed.
32. Neuzil J., Stocker R. Free and albumin-bound bilirubin are efficient coantioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 1994, 269:16712-16719.
33. Chung H.T., Pae H.O., Cha Y.N. Role of heme oxygenase-1 in vascular disease. Curr Pharm Des 2008, 14:422-428.
34. Wu T.W., Fung K.P., Wu J., et al. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol 1996, 51:859-862.
35. Vítek L., Schwertner H.A. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem 2007, 43:1-57.
36. Schwertner H.A. Association of smoking and low serum bilirubin antioxidant concentrations. Atherosclerosis 1998, 136:383-387.
37. Morita T. Heme oxygenase and atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:1786-1795.
38. Vítek L., Jirsa M., Brodanová M., et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002, 160:449-456.
39. Siow R.C.M., Sato H., Mann G.E. Heme oxygenase-carbon monoxide signaling pathway in atherosclerosis: anti-atherogenic actions of bilirubin and carbon monoxide?. Cardiovasc Res 1999, 41:385-394.
40. Pepys M.B., Baltz M.L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983, 34:141-212.
41. Snyder S.H., Barañano D.E. Heme oxygenase: a font of multiple messengers. Neuropsychopharmacology 2001, 25:294-298.
42. Li M., Kim D.H., Tsenovoy P.L., et al. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes 2008, 57:1526-1535.
43. Pflueger A., Croatt A.J., Peterson T.E., et al. The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II. Am J Physiol Ren Physiol 2005, 288(3):552-558.
44. Datla S.R., Dusting G.J., Mori T.A., et al. Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress. Hypertension 2007, 50:636-642.
45. Ollinger R., Bilban M., Erat A., et al. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 2005, 112:1030-1039.
46. Andersson C., Weeke P., Fosbøl E.L., et al. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism 2009, 58:1109-1115.